TET2 mutation can precede JAK2 mutations in MPN HSCs and lead to biclonal disease or can occur secondary to JAK2V617F mutation and provide a competitive advantage driving clonal dominance [122]. This evidence concerns the gene TET2 and myeloproliferative neoplasm.